LncRNA MEG3 acts a biomarker and regulates cell functions by targeting ADAR1 in colorectal cancer

Table 3 Univariate and multivariate survival analysis

Variables	Univariate analysis			Multivariate analysis
	HR	95%CI	P value	HR	95%CI	P value
Age in yr, ≥ 60 vs < 60	0.806	0.481-1.352	0.414	- - -	- - -	- - -
Gender, male vs female	1.265	0.757-2.178	0.396	- - -	- - -	- - -
Tumor site, colon vs rectum	0.681	0.405-1.143	0.146	- - -	- - -	- - -
Tumor size in cm, ≥ 5 vs < 5	0.576	0.342-0.968	0.037	0.436	0.236-0.806	0.008
pT of TNM, T1 + T2 vs T3 + T4	0.572	0.332-0.986	0.044	0.942	0.477-1.861	0.863
Lymph node metastasis, positive vs negative	0.988	0.591-1.651	0.964	- - -	- - -	- - -
Clinical stage of TNM, III vs I + II	0.225	0.122-0.414	0.001	0.039	0.012-0.124	0.001
Pathological differentiation, well/moderate vs poor	0.440	0.258-0.752	0.003	0.641	0.324-1.267	0.201
Serum lncRNA MEG3 expression, high vs low	2.789	1.615-4.816	0.001	0.173	0.063-0.480	0.002

TNM: Tumor node metastasis; lncRNA: Long non-coding RNAs; MEG3: Maternally expressed gene 3; CI: Confidence interval; HR: Hazard ratio.